Somewhere on a pharmacy shelf sits a drug that could be treating cancer right now. It is approved, it is inexpensive, and in many cases, the clinical evidence to support a new use already exists in the scientific literature. What is missing is not the science. It is a business model.

That gap became personal for Dr. Laura Kleiman years before she named it a market failure. She was running a data science research center at Dana-Farber Cancer Institute when her mother became a patient there. Reviewing the literature, she kept encountering studies on generic drugs tested for new cancer applications. Some were directly relevant to her mother’s diagnosis, yet no one was advancing them.

Medical innovation does not always mean inventing something new. Sometimes it means finding new value in what already exists.

A Market With No Owner

The economics explain the neglect. When a treatment is a generic, no single manufacturer can capture enough return to justify the steep cost of clinical trials for a new indication. Every competitor selling the same compound would benefit equally from the investment. The result is a landscape of promising treatments that patients could use, but clinicians never hear about. Kleiman left Dana-Farber and founded Reboot Rx to own a problem that falls squarely between institutional incentives.

Finding Signal in Half a Million Studies

Oncology has produced a vast body of literature, far more than any human team could review manually. Reboot Rx addresses this through a distinct methodology:

  • AI-Driven Literature Synthesis: Machine learning models synthesize findings across more than 500,000 published cancer studies, ranking drug-cancer pairings by clinical promise.
  • Expert Curation: Technology surfaces signal, but human judgment directs action. Biomedical scientists and clinical experts evaluate top-ranked candidates to determine next steps such as additional evidence, regulatory groundwork, or clinician education.

Proof Is Not the Same as Practice

Even a completed clinical trial does not guarantee adoption. Kleiman calls this one of the hardest lessons of building Reboot Rx. Funders often assume that a published result leads directly to bedside use, but generic drugs lack the massive commercial sales and marketing engines that drive adoption for patented therapeutics.

To bridge this translation gap, Reboot Rx is tapping trusted clinical channels including national treatment guidelines, Continuing Medical Education programs, and emerging clinical decision support tools. Funding this neglected pipeline requires forward-looking philanthropic partners like Arnold Ventures, the Pershing Square Foundation, and the DRK Foundation, who recognize that these trials cannot happen without catalytic capital.

Owning the Problem Across Institutions

While government entities possess critical capabilities ranging from the National Cancer Institute generating evidence to the FDA setting regulatory pathways, no single agency owns the end-to-end pipeline.

A nonprofit can own the problem across institutional boundaries in a way no single agency, university, or corporation can.

Reboot Rx is now preparing its first major clinical trial for an inexpensive generic cancer treatment, powered by a model blending nonprofit leadership, philanthropy, and public research infrastructure. Kleiman’s broader ambition is systemic: turning drug repurposing from a series of lucky accidents into a routine, scalable standard of care.

To learn more about Reboot Rx or support the mission, visit rebootrx.org.

Share This: